Factor V deficiency in Philadelphia-positive chronic myelogenous leukemia

D. K. Hasegawa, A. J. Bennett, Peter Felix Coccia, N. K. Ramsay, M. E. Nesbit, W. Krivit, J. R. Edson

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Factor V deficiency has been identifed in 8 of 8 patients 7-20 yr of age, with Philadelphia-positive (Ph 1 +) chronic myelogenous leukemia (CML). In these 8 patients, factor V deficiency was not due to hepatic dysfunction, factor V inhibitors, or disseminated intravascular coagulation. In 3 patients, factor V activity rose 10%-12% (0.10-0.12 U/ml) after the infusion of 28-31 ml/kg body weight of fresh frozen plasma (FFP). The rise persisted less than 14 hr. The mean measured postinfusion rise in factor V was 18% of the expected rise calculated from the volume of FFP infused in the patients' plasma volume. In 4 patients, a small transient rise in factor V activity occurred after splenectomy or plateletpheresis. Factor V deficiency was completely corrected after a marked reduction in bone marrow cellularity in 2 patients with Ph 1 + CML treated with extensive chemotherapy, total body irradiation, and bone marrow transplantation. Factor V deficiency was retrospectively observed in 6 of 20 patients, ages 20-80 yr, with Ph 1 + CML and 3 of 6 patients with other myeloproliferative disorders. The factor V deficiency appears to be associated with the large myeloid-megakaryocytic cell mass characteristic of CML and other myeloproliferative disorders.

Original languageEnglish (US)
Pages (from-to)585-595
Number of pages11
JournalBlood
Volume56
Issue number4
StatePublished - Dec 15 1980

Fingerprint

Factor V Deficiency
Factor V
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Myeloproliferative Disorders
Plasmas
Bone
Plateletpheresis
Chemotherapy
Coagulation
Plasma Volume
Disseminated Intravascular Coagulation
Whole-Body Irradiation
Splenectomy
Myeloid Cells
Bone Marrow Transplantation
Irradiation
Bone Marrow
Body Weight
Drug Therapy

ASJC Scopus subject areas

  • Biochemistry
  • Immunology
  • Hematology
  • Cell Biology

Cite this

Hasegawa, D. K., Bennett, A. J., Coccia, P. F., Ramsay, N. K., Nesbit, M. E., Krivit, W., & Edson, J. R. (1980). Factor V deficiency in Philadelphia-positive chronic myelogenous leukemia. Blood, 56(4), 585-595.

Factor V deficiency in Philadelphia-positive chronic myelogenous leukemia. / Hasegawa, D. K.; Bennett, A. J.; Coccia, Peter Felix; Ramsay, N. K.; Nesbit, M. E.; Krivit, W.; Edson, J. R.

In: Blood, Vol. 56, No. 4, 15.12.1980, p. 585-595.

Research output: Contribution to journalArticle

Hasegawa, DK, Bennett, AJ, Coccia, PF, Ramsay, NK, Nesbit, ME, Krivit, W & Edson, JR 1980, 'Factor V deficiency in Philadelphia-positive chronic myelogenous leukemia', Blood, vol. 56, no. 4, pp. 585-595.
Hasegawa DK, Bennett AJ, Coccia PF, Ramsay NK, Nesbit ME, Krivit W et al. Factor V deficiency in Philadelphia-positive chronic myelogenous leukemia. Blood. 1980 Dec 15;56(4):585-595.
Hasegawa, D. K. ; Bennett, A. J. ; Coccia, Peter Felix ; Ramsay, N. K. ; Nesbit, M. E. ; Krivit, W. ; Edson, J. R. / Factor V deficiency in Philadelphia-positive chronic myelogenous leukemia. In: Blood. 1980 ; Vol. 56, No. 4. pp. 585-595.
@article{f87a4930c9224293baffaed650bc64dd,
title = "Factor V deficiency in Philadelphia-positive chronic myelogenous leukemia",
abstract = "Factor V deficiency has been identifed in 8 of 8 patients 7-20 yr of age, with Philadelphia-positive (Ph 1 +) chronic myelogenous leukemia (CML). In these 8 patients, factor V deficiency was not due to hepatic dysfunction, factor V inhibitors, or disseminated intravascular coagulation. In 3 patients, factor V activity rose 10{\%}-12{\%} (0.10-0.12 U/ml) after the infusion of 28-31 ml/kg body weight of fresh frozen plasma (FFP). The rise persisted less than 14 hr. The mean measured postinfusion rise in factor V was 18{\%} of the expected rise calculated from the volume of FFP infused in the patients' plasma volume. In 4 patients, a small transient rise in factor V activity occurred after splenectomy or plateletpheresis. Factor V deficiency was completely corrected after a marked reduction in bone marrow cellularity in 2 patients with Ph 1 + CML treated with extensive chemotherapy, total body irradiation, and bone marrow transplantation. Factor V deficiency was retrospectively observed in 6 of 20 patients, ages 20-80 yr, with Ph 1 + CML and 3 of 6 patients with other myeloproliferative disorders. The factor V deficiency appears to be associated with the large myeloid-megakaryocytic cell mass characteristic of CML and other myeloproliferative disorders.",
author = "Hasegawa, {D. K.} and Bennett, {A. J.} and Coccia, {Peter Felix} and Ramsay, {N. K.} and Nesbit, {M. E.} and W. Krivit and Edson, {J. R.}",
year = "1980",
month = "12",
day = "15",
language = "English (US)",
volume = "56",
pages = "585--595",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "4",

}

TY - JOUR

T1 - Factor V deficiency in Philadelphia-positive chronic myelogenous leukemia

AU - Hasegawa, D. K.

AU - Bennett, A. J.

AU - Coccia, Peter Felix

AU - Ramsay, N. K.

AU - Nesbit, M. E.

AU - Krivit, W.

AU - Edson, J. R.

PY - 1980/12/15

Y1 - 1980/12/15

N2 - Factor V deficiency has been identifed in 8 of 8 patients 7-20 yr of age, with Philadelphia-positive (Ph 1 +) chronic myelogenous leukemia (CML). In these 8 patients, factor V deficiency was not due to hepatic dysfunction, factor V inhibitors, or disseminated intravascular coagulation. In 3 patients, factor V activity rose 10%-12% (0.10-0.12 U/ml) after the infusion of 28-31 ml/kg body weight of fresh frozen plasma (FFP). The rise persisted less than 14 hr. The mean measured postinfusion rise in factor V was 18% of the expected rise calculated from the volume of FFP infused in the patients' plasma volume. In 4 patients, a small transient rise in factor V activity occurred after splenectomy or plateletpheresis. Factor V deficiency was completely corrected after a marked reduction in bone marrow cellularity in 2 patients with Ph 1 + CML treated with extensive chemotherapy, total body irradiation, and bone marrow transplantation. Factor V deficiency was retrospectively observed in 6 of 20 patients, ages 20-80 yr, with Ph 1 + CML and 3 of 6 patients with other myeloproliferative disorders. The factor V deficiency appears to be associated with the large myeloid-megakaryocytic cell mass characteristic of CML and other myeloproliferative disorders.

AB - Factor V deficiency has been identifed in 8 of 8 patients 7-20 yr of age, with Philadelphia-positive (Ph 1 +) chronic myelogenous leukemia (CML). In these 8 patients, factor V deficiency was not due to hepatic dysfunction, factor V inhibitors, or disseminated intravascular coagulation. In 3 patients, factor V activity rose 10%-12% (0.10-0.12 U/ml) after the infusion of 28-31 ml/kg body weight of fresh frozen plasma (FFP). The rise persisted less than 14 hr. The mean measured postinfusion rise in factor V was 18% of the expected rise calculated from the volume of FFP infused in the patients' plasma volume. In 4 patients, a small transient rise in factor V activity occurred after splenectomy or plateletpheresis. Factor V deficiency was completely corrected after a marked reduction in bone marrow cellularity in 2 patients with Ph 1 + CML treated with extensive chemotherapy, total body irradiation, and bone marrow transplantation. Factor V deficiency was retrospectively observed in 6 of 20 patients, ages 20-80 yr, with Ph 1 + CML and 3 of 6 patients with other myeloproliferative disorders. The factor V deficiency appears to be associated with the large myeloid-megakaryocytic cell mass characteristic of CML and other myeloproliferative disorders.

UR - http://www.scopus.com/inward/record.url?scp=0018956742&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0018956742&partnerID=8YFLogxK

M3 - Article

VL - 56

SP - 585

EP - 595

JO - Blood

JF - Blood

SN - 0006-4971

IS - 4

ER -